MedTrace Logo

Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age

NCT05444699 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-02-13

No results posted yet for this study

Summary

The aim of the trial is to evaluate whether the use of oral prednisolone directed by point-of-care testing is useful in acute wheezing caused by rhinovirus in children aged 6-24 months.

Conditions

  • Bronchiolitis Acute Viral

Interventions

DRUG

Prednisolone Sodium Phosphate

Oral suspension administered 1 mg/kg once a day for three days

DRUG

Sugar syrup

Oral suspension administered the same amount in milliliters as experimental product once a day for three days

Sponsors & Collaborators

  • University of Oulu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2026-12-31
Completion
2027-09-30

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05444699 on ClinicalTrials.gov